Enlivex
Prof. Dror Mevorach, M.D., Enlivex’s founder, has been the Chief Scientific & Medical Officer since 2009.
Prof. Mevorach is a leading scientist on the removal of apoptotic cells and the Co-Chaired several Apoptotic Cell Recognition and Clearance at Gordon Research Conference and in international meetings. Prof. Mevorach is currently the Chairman of Medicine, and the Director of the Rheumatology Research Centre of Hadassah-Hebrew University Hospital and School of Medicine in Jerusalem.
Prof. Mevorach published more than 100 scientific papers and is a frequent lecturer at international conferences. Prof. Mevorach earned his M.D. (Cum Laude) from The Technion – Israel Institute of Technology in Haifa, Israel, and was a fellow at the Hospital for Special Surgery and Cornell Medical School, NY.
This person is not in any offices
Enlivex
Enlivex's mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, Enlivex intends to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses.